Savara (NASDAQ:SVRA) Price Target Raised to $9.00

Savara (NASDAQ:SVRA) had its target price boosted by Wells Fargo & Company from $7.00 to $9.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

SVRA has been the topic of a number of other reports. Lifesci Capital raised Savara to a “strong-buy” rating in a report on Tuesday, October 14th. Oppenheimer increased their target price on shares of Savara from $8.00 to $9.00 and gave the company an “outperform” rating in a research report on Friday, November 14th. HC Wainwright boosted their price target on shares of Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Guggenheim upped their price target on shares of Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Finally, Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.57.

Savara Stock Performance

SVRA opened at $6.05 on Thursday. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $4.94 and its 200-day moving average is $3.58. The stock has a market cap of $1.23 billion, a PE ratio of -11.42 and a beta of 0.23. Savara has a twelve month low of $1.89 and a twelve month high of $7.01.

Savara (NASDAQ:SVRA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). On average, analysts predict that Savara will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SVRA. VR Adviser LLC lifted its position in shares of Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock valued at $20,256,000 after acquiring an additional 5,626,624 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its position in shares of Savara by 20.8% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock valued at $48,754,000 after purchasing an additional 3,035,164 shares during the period. Frazier Life Sciences Management L.P. increased its stake in Savara by 32.4% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock worth $31,751,000 after purchasing an additional 2,801,922 shares in the last quarter. Rosalind Advisors Inc. increased its stake in Savara by 50.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock worth $14,280,000 after purchasing an additional 1,345,056 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Savara during the 3rd quarter worth about $3,014,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.